

October 3, 2011



## **XOMA Presents Data on Novel Antitoxins in Development for Botulism Poisoning**

BERKELEY, Calif., Oct. 3, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced several presentations highlighting its expertise in the development of recombinant antitoxins for botulism poisoning. The presentations will be made at the Seventh Triennial Basic and Therapeutic Aspects of Botulinum and Tetanus (Toxins 2011), and the 48<sup>th</sup> Annual Interagency Botulism Research Coordinating Committee (IBRCC) conferences. The Toxins 2011 conference is being held from October 2 to 5, and the IBRCC conference from October 5 to 7, 2011, both in Santa Fe, New Mexico.

Presentations at the Toxins 2011 conference:

- Recombinant monoclonal antibody based antitoxins for treatment of Type A, B and E botulism –Abstract #B52, Monday Oct 3, 5:30-7PM
- Nonclinical safety evaluation of XOMA 3AB, a novel triple antibody drug product targeting botulinum toxin Type A, in Sprague-Dawley rats – Abstract B32, Monday Oct 3, 5:30-7 PM

Presentations at the IBRCC conference:

- Development of a room temperature-stable lyophilized formulation for anti-botulinum E toxin (BoNT/E) antibody cocktail XOMA 3EB – Abstract #CM-4, Thursday Oct 6, 4 – 5PM
- Development of a platform for rapid purification of botulinum neurotoxin sub-domains Type A, B and E – Abstract #CM-11, Thursday Oct 6, 4 – 5 PM
- Development of stability-indicating methods for mixed monoclonal antibody drug products to neutralize botulinum neurotoxin Types A, B and E – Abstract CM-3, Thursday Oct 6, 4- 5 PM
- Recombinant monoclonal antibody based antitoxins for treatment of Type A, B and E botulism - Thursday Oct 6, 3:30 – 3:50 PM

Also today, XOMA announced expansion of its botulism antitoxin program through the award of a new contract for up to \$28 million over five years to develop monoclonal antibody-based antitoxins for Type C and Type D botulinum toxins. With this new award, from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health, XOMA has entered into four NIAID contracts totaling up to approximately \$120 million for anti-botulism product development.

XOMA's botulism antitoxin programs are based on more than a decade of breakthrough

biomedical research conducted in the laboratory of James D. Marks, M.D., Ph.D., Professor of Anesthesia at the University of California, San Francisco (UCSF) and on XOMA's extensive technical expertise and platform technologies in the antibody field. The UCSF research demonstrated for the first time that multiple whole antibodies can achieve maximum effectiveness against botulinum toxins at very low doses.

## **About Botulism**

Botulism is a muscle-paralyzing disease caused by one of the most potent known toxins, a neurotoxin made by the bacterium *Clostridium botulinum*. Exposure to the botulinum neurotoxin can cause muscle paralysis that can eventually lead to death. Botulism can be acquired through consumption of contaminated foods or through infection of a wound. Due to the risk posed by the botulinum neurotoxin as a biological weapon and the severity of disease, it has been classified by the U.S. government as a Category A bioterrorism agent.

## **About XOMA**

XOMA is a leader in the discovery and development of novel antibody therapeutics. The company's proprietary product pipeline includes:

- XOMA 052, a humanized antibody that binds to the inflammatory cytokine interleukin-1 beta, or IL-1 beta. XOMA plans to enter XOMA 052 into Phase 3 clinical development in Behcet's uveitis, an orphan indication. Les Laboratoires Servier is XOMA's development and commercialization partner for XOMA 052.
- Antibodies against botulinum toxins, led by XOMA 3AB, a novel combination of three antibodies to prevent and treat botulism poisoning caused by exposure to botulinum neurotoxin Type A, among the most deadly bioterror threats. XOMA 3AB is in a Phase 1 clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Development of these antibodies has been funded in whole or in part with funds from NIAID, NIH, Department of Health and Human Services under Contract No. HHSN266200500004C, Contract No. HHSN266200600008C, Contract No. HHSN272200800028C, Contract No. HHSN266200600011C, Contract No., HHSN272200800026C, and Contract No. HHSN2722011031C.
- A preclinical pipeline with candidates in development for autoimmune, cardio-metabolic, inflammatory and oncological diseases. Among these are two new classes of fully human monoclonal antibodies that activate (XMetA) or sensitize (XMetS) the insulin receptor in vivo, which represent distinct new therapeutic approaches to the treatment of patients with diabetes.

XOMA has a premier antibody discovery and development platform that incorporates an unmatched collection of antibody phage display libraries and proprietary optimization and expression and manufacturing technologies that it uses for its own pipeline and in collaborations with pharmaceutical and biotechnology companies. XOMA's fully integrated product development infrastructure extends from preclinical science to approval and is located in Berkeley, California. For more information, please visit [www.xoma.com](http://www.xoma.com).

The XOMA Ltd. logo is available at <https://www.globenewswire.com/newsroom/prs/?pkgid=5960>

## **Forward-Looking Statements**

Certain statements contained herein concerning government contracts, product development and/or strategic goals or that otherwise relate to future periods are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. Among other things, our actual revenues under our new contract may be lower than expected if we are unable to satisfy NIAID of our progress in development of these product candidates or if NIAID has insufficient funds with which to continue funding the development of these product candidates or due to unanticipated research, development, regulatory, safety, manufacturing, quality or other issues; and our product candidates may not received the U.S. Food and Drug Administration approval or Emergency Use Authorization required to be considered for inclusion in the Strategic National Stockpile, and even if safe and effective the product candidates may not be added to the Strategic National Stockpile due to medical, scientific, competitive, funding or other reasons.

These and other risks, including the generally unstable nature of current economic and financial market conditions; the results of discovery research and preclinical testing; the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the FDA, European or other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data); XOMA's ability to meet the demands of the United States government agency with which it has entered into its government contracts; competition; scale-up, manufacturing and marketing capabilities; changes in the status of existing collaborative and licensing relationships; the ability of collaborators, licensees and other third parties to meet their obligations and their discretion in decision-making; market demand for products; availability of additional licensing or collaboration opportunities; international operations; share price volatility; XOMA's financing needs and opportunities; uncertainties regarding the status of biotechnology patents; uncertainties as to the costs of protecting intellectual property; and risks associated with XOMA's status as a Bermuda company, are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings. Consider such risks carefully when considering XOMA's prospects.

## **University of California Disclaimer for Industry Releases**

The information stated above was prepared by XOMA and reflects solely the opinion of XOMA. Nothing in this statement shall be construed to imply any support or endorsement of XOMA, or any of its products, by The Regents of the University of California, its officers, agents and employees.

CONTACT: XOMA Ltd.  
Company and Investor Contact:  
Carol DeGuzman  
510-204-7270  
[deguzman@xoma.com](mailto:deguzman@xoma.com)

Canale Communications

Media Contact:  
Carolyn Hawley  
619-849-5375  
[carolyn@canalecomm.com](mailto:carolyn@canalecomm.com)

Source: XOMA Ltd.